Los receptores nucleares como nuevas dianas terapéuticas para un manejo integral de las dislipemias

2001, JAMA, 285, 2486, 10.1001/jama.285.19.2486

1998, Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel, Arch Intern Med, 148, 36

1993, Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, JAMA, 269, 3015, 10.1001/jama.1993.03500230097036

Mangelsdorf, 1995, The nuclear receptor superfamily: the second decade, Cell, 83, 835, 10.1016/0092-8674(95)90199-X

Giguere, 1999, Orphan nuclear receptors: from gene to function, Endocr Rev, 20, 689, 10.1210/er.20.5.689

Chawla, 2001, Nuclear receptors and lipid physiology: opening the X-files, Science, 294, 1866, 10.1126/science.294.5548.1866

Desvergne, 1999, Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev, 20, 649, 10.1210/er.20.5.649

Torra, 2001, Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice, Curr Opin Lipidol, 12, 245, 10.1097/00041433-200106000-00002

Peet, 1998, The LXRs: a new class of oxysterol receptors, Curr Opin Genet Dev, 8, 571, 10.1016/S0959-437X(98)80013-0

Tu, 2000, FXR, a bile acid receptor and biological sensor, Trends Cardiovasc Med, 10, 30, 10.1016/S1050-1738(00)00043-8

Rastinejad, 2001, Retinoid X receptor and its partners in the nuclear receptor family, Curr Opin Struct Biol, 11, 33, 10.1016/S0959-440X(00)00165-2

Fruchart, 2001, The role of fibric acids in therosclerosis, Curr Atheroscler Rep, 3, 83, 10.1007/s11883-001-0015-x

Mudaliar, 2001, New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers, Annu Rev Med, 52, 239, 10.1146/annurev.med.52.1.239

Martens, 2002, Metabolic and additional vascular effects of thiazolidinediones, Drugs, 62, 1463, 10.2165/00003495-200262100-00004

Parulkar, 2001, Nonhypoglycemic effects of thiazolidinediones, Ann Intern Med, 134, 61, 10.7326/0003-4819-134-1-200101020-00014

Chinetti, 2001, PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway, Nat Med, 7, 53, 10.1038/83348

Boyle, 2002, Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records, Clin Ther, 24, 378, 10.1016/S0149-2918(02)85040-8

Khan, 2002, Prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone, Diabetes Care, 25, 708, 10.2337/diacare.25.4.708

Koshiyama, 2001, Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes, J Clin Endocrinol Metab, 86, 3452, 10.1210/jc.86.7.3452

Oliver, 2001, A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport, Proc Natl Acad Sci USA, 98, 5306, 10.1073/pnas.091021198

Repa, 2000, The role of orphan nuclear receptors in the regulation of cholesterol homeostasis, Annu Rev Cell Dev Biol, 16, 459, 10.1146/annurev.cellbio.16.1.459

Janowski, 1996, An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha, Nature, 383, 728, 10.1038/383728a0

Makishima, 1999, Identification of a nuclear receptor for bile acids, Science, 284, 1362, 10.1126/science.284.5418.1362

Repa, 2000, Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers, Science, 289, 1524, 10.1126/science.289.5484.1524

Laffitte, 2001, LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes, Proc Natl Acad Sci USA, 98, 507, 10.1073/pnas.98.2.507

Luo, 2000, Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element, J Clin Invest, 105, 513, 10.1172/JCI8573

Schultz, 2000, Role of LXRs in control of lipogenesis, Genes Dev, 14, 2831, 10.1101/gad.850400

Repa, 2000, Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta, Genes Dev, 14, 2819, 10.1101/gad.844900

Joseph, 2002, Synthetic LXR ligand inhibits the development of atherosclerosis in mice, Proc Natl Acad Sci USA, 99, 7604, 10.1073/pnas.112059299

Sinal, 2000, Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis, Cell, 102, 731, 10.1016/S0092-8674(00)00062-3

Kast, 2001, Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids, Mol Endocrinol, 15, 1720, 10.1210/me.15.10.1720

Sinal, 2000, Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis, Cell, 102, 731, 10.1016/S0092-8674(00)00062-3

Urizar, 2002, A natural product that lowers cholesterol as an antagonist ligand for FXR, Science, 96, 1703, 10.1126/science.1072891

Agarwal, 1986, Clinical trial of gugulipid — a new hypolipidemic agent of plant origin in primary hyperlipidemia, Indian J Med Res, 84, 626

Nityanand, 1989, Clinical trials with gugulipid. A new hypolipidaemic agent, J Assoc Physicians India, 37, 323

Lenhard, 1999, The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction, Diabetologia, 42, 545, 10.1007/s001250051193

Claudel, 2001, Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor, Proc Natl Acad Sci USA, 98, 2610, 10.1073/pnas.041609298